Boehringer Ingelheim announces option of PRADAXA in U.

‘PRADAXA gets the potential to considerably impact the procedure paradigm for sufferers with non-valvular atrial fibrillation. We will work with insurers to create PRADAXA as inexpensive and accessible as feasible.’ PRADAXA 150mg used twice daily offers been shown to considerably decrease stroke and systemic embolism by 35 % beyond the decrease accomplished with warfarin, the existing standard of look after patients with non-valvular atrial fibrillation.. Boehringer Ingelheim announces option of PRADAXA in U.S. Pharmacies Boehringer Ingelheim Pharmaceuticals, Inc.S. Food and Medication Administration accepted PRADAXA on October 19, 2010 to lessen the chance of stroke and systemic embolism in sufferers with non-valvular atrial fibrillation.The release of the cases is an important next thing toward our goal of improving health care delivery through global collaboration and is representative of Brigham and Women’s Hospital’s dedication to reducing wellness disparities for all communities. We are especially gratified to be able to aid those global practitioners and educators for whom access to such high-quality information has been unattainable, said Dr. Elizabeth Nabel, President of Brigham and Women’s Hospital. The GHD Task aims to market case-based learning globally by hosting faculty training workshops across Africa and because they build a network of global health delivery educators.

Calif. Conjoined twins separated: How are they? Conjoined twins Angelica and Angelina Sabuco were separated Tuesday, following a nine-hour operation.